Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD34 PerCP-Cy™5.5

Anti-Hu CD34 PerCP-Cy™5.5

Regulatory status

RUO

Antigen

CD34

Clone

581

Format

PerCP-Cy™5.5

Reactivity

Non-human primates, Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

T9-664-T100

In stock

420.00 USD

25 tests

T9-664-T025

Delivery 1 week

210.00 USD

Variant

100 tests

T9-664-T100

In stock

420.00 USD

25 tests

T9-664-T025

Delivery 1 week

210.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody 581 reacts with an extracellular epitope of CD34, a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody recognizes the class III CD34 epitope resistant to neuraminidase, chymopapain and glycoprotease.

Workshop

HLDA V: WS Code MA27

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Non-human primates, Human

Negative species

Sheep

Preparation

Purified antibody is conjugated with activated tandem dye of activated Peridinin-Chlorophyll Protein-Cyanine 5.5 (PerCP-Cy™5.5) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Cy™ and CyDye™ are registered trademarks of Cytiva.

Antigen description

CD34 is a highly glycosylated monomeric 111-115 kDa surface protein, which is present on many stem cell populations. It is a well established stem cell marker, though its expression on human hematopoietic stem cells is reversible. CD34 probably serves as a surface receptor that undergoes receptor-mediated endocytosis and regulates adhesion, differentiation and proliferation of hematopoietic stem cells and other progenitors. CD34 expression is likely to represent a specific state of hematopoietic development that may have altered adhering properties with expanding and differentiating capabilities in both in vitro and in vivo conditions.

Entrez Gene ID 947

UniProt ID P28906

Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD34 (581) PerCP-Cy™5.5 antibody (4 μl reagent / 100 μl of peripheral whole blood).

Separation of human CD34 positive stem cells (red-filled) from lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD34 (581) PerCP-Cy™5.5 antibody (4 μl reagent / 100 μl of peripheral whole blood).

General references:

Krauter J, Hartl M, Hambach L, Kohlenberg A, Gunsilius E, Ganser A, Heil G: Receptor-mediated endocytosis of CD34 on hematopoietic cells after stimulation with the monoclonal antibody anti-HPCA-1. J Hematother Stem Cell Res. 2001 Dec;10(6):863-71.
PubMed

Dao MA, Arevalo J, Nolta JA: Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution. Blood. 2003 Jan 1;101(1):112-8.
PubMed

Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Gulati S, Luthra PM: Three-dimensional structure prediction of the interaction of CD34 with the SH3 domain of Crk-L. Stem Cells Dev. 2005 Oct;14(5):470-7.
PubMed

Gangenahalli GU, Singh VK, Verma YK, Gupta P, Sharma RK, Chandra R, Luthra PM: Hematopoietic stem cell antigen CD34: role in adhesion or homing. Stem Cells Dev. 2006 Jun;15(3):305-13.
PubMed

Product specific references:

Sanz E, Muñoz-A N, Monserrat J, Van-Den-Rym A, Escoll P, Ranz I, Alvarez-Mon M, de-la-Hera A: Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5925-30.
PubMed

Goardon N, Nikolousis E, Sternberg A, Chu WK, Craddock C, Richardson P, Benson R, Drayson M, Standen G, Vyas P, Freeman S: Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes. Haematologica. 2009 Aug;94(8):1160-3.
PubMed

Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T: Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation. 2006 Mar 14;113(10):1311-25.
PubMed

Ninos JM, Jefferies LC, Cogle CR, Kerr WG: The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med. 2006 Feb 16;4:9.
PubMed

Ono F, Sharma BK, Smith CC, Burnett JW, Aurelian L: CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM).J Invest Dermatol. 2005 Jun;124(6):1215-24.
PubMed

Suárez L, Vidriales MB, García-Laraña J, Sanz G, Moreno MJ, López A, Barrena S, Martínez R, Tormo M, Palomera L, Lavilla E, López-Berges MC, de Santiago M, de Equiza ME, Miguel JF, Orfao A: CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res. 2004 Nov 15;10(22):7599-606.
PubMed

Kato S, Ando K, Nakamura Y, Muguruma Y, Sato T, Yabe H, Yabe M, Hattori K, Yasuda Y, Hotta T: Absence of a CD34- hematopoietic precursor population in recipients of CD34+ stem cell transplantation. Bone Marrow Transplant. 2001 Sep;28(6):587-95.
PubMed

Felschow DM, McVeigh ML, Hoehn GT, Civin CI, Fackler MJ: The adapter protein CrkL associates with CD34. Blood. 2001 Jun 15;97(12):3768-75.
PubMed

Janowska-Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montaño J, Chang H, Rozmus J, Russell JA, Edwards DR, Turner AR: Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999 May 15;93(10):3379-90.
PubMed

Ando K, Nakamura Y, Chargui J, Matsuzawa H, Tsuji T, Kato S, Hotta T: Extensive generation of human cord blood CD34(+) stem cells from Lin(-)CD34(-) cells in a long-term in vitro system. Exp Hematol. 2000 Jun;28(6):690-9.
PubMed

Bonelli P, Nicolussi P, Manetti R, Antuofermo E, Dattena M: Monoclonal antigen do not cross-react with ovine umbilical cord blood cells. Ital J Anim Sci 2010, vol.9:e6.
PubMed